Loading...
•
Sep 30, 2024
Kala Bio Q3 2024 Earnings Report
KALA BIO reported financial results for the third quarter ended September 30, 2024 and provided a corporate update.
Key Takeaways
KALA BIO reported a net loss of $9.0 million, or $1.93 per share, for the third quarter ended September 30, 2024. The company had cash and cash equivalents of $49.2 million as of September 30, 2024.
KALA is enrolling patients in the Phase 2b CHASE trial for PCED treatment, with topline data expected in Q2 2025.
The company initiated five clinical trial sites in Argentina for the CHASE trial and is planning additional sites in Latin America.
KALA is exploring KPI-012 for additional rare, front-of-the-eye diseases, including Limbal Stem Cell Deficiency (LSCD).
KALA had cash and cash equivalents of $49.2 million as of September 30, 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...